Sign up
Pharma Capital

LexaGene Holdings tackles rapid pathogen detection

LexaGene Holdings (CVE:LXG) President Daryl Rebeck tells Proactive Investors about how the biotech company continues to develop and commercialize pathogen detection devices in the biochemical industry.

Rebeck says pathogens are anything that can make us ill, such as salmonella, E. coli, respiratory diseases, Lyme disease. The instrument LexaGene offers quickly detects multiple pathogens with sensitivity and specificity.

"It's a very easy-to-use instrument," says Rebeck.

The platform could be used in food safety, veterinary diagnostics, water quality monitoring, aquaculture pathogen surveillance, and other markets.

 

View full LXG profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.